Scribe Therapeutics (SCTX) Stock Overview
Operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
SCTX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Scribe Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$29.41 |
| 52 Week High | US$39.60 |
| 52 Week Low | US$17.31 |
| Beta | 0 |
| 1 Month Change | 17.97% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 35.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| SCTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.8% | -2.6% | 0.9% |
| 1Y | n/a | 38.4% | 15.5% |
Return vs Industry: Insufficient data to determine how SCTX performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how SCTX performed against the US Market.
Price Volatility
| SCTX volatility | |
|---|---|
| SCTX Average Weekly Movement | 19.8% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SCTX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine SCTX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 82 | Benjamin Oakes | www.scribetx.com |
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with elevated Lp(a); and STX-1400 is designed to target and remove the transcriptional start site of the APOC3 gene and strongly reduce mRNA expression. It uses CRISPR-based platforms, such as ELXR, designed for precise, durable epigenetic silencing of genes without changing the underlying DNA sequence; and XE, designed to support specific and efficient gene editing.
Scribe Therapeutics Inc. Fundamentals Summary
| SCTX fundamental statistics | |
|---|---|
| Market cap | US$593.32m |
| Earnings (TTM) | -US$32.30m |
| Revenue (TTM) | US$33.30m |
Is SCTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SCTX income statement (TTM) | |
|---|---|
| Revenue | US$33.30m |
| Cost of Revenue | US$51.05m |
| Gross Profit | -US$17.74m |
| Other Expenses | US$14.56m |
| Earnings | -US$32.30m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.71 |
| Gross Margin | -53.29% |
| Net Profit Margin | -97.00% |
| Debt/Equity Ratio | -85.0% |
How did SCTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/09 00:34 |
| End of Day Share Price | 2026/09/09 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Scribe Therapeutics Inc. is covered by 5 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Richard J. Law | Goldman Sachs |
| Debjit Chattopadhyay | Guggenheim Securities, LLC |
| Mitchell Kapoor | H.C. Wainwright & Co. |